Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials

Article Dermatology

Characterizing the relationships between patient-reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib

R. Winnette et al.

Summary: This study evaluated the efficacy and impact of ritlecitinib and brepocitinib on patients with alopecia areata through the ALLEGRO trial. The patient-reported outcome tool AASIS showed correlation with clinician-assessed SALT scores, and both ritlecitinib and brepocitinib groups had significant improvements in symptom and severity scores at week 24 compared to placebo.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

添加到收藏夹

Editorial Material Medicine, General & Internal

Baricitinib in Alopecia Areata

Andrew Messenger et al.

Summary: For many individuals, alopecia areata is a temporary issue with hair loss patches recovering spontaneously within a few months. However, for a significant portion of patients, this condition can persist long-term and progress to complete baldness, with limited chances of recovery. Severe cases of alopecia often do not respond to medical treatments, leaving patients to struggle with the challenges it presents.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Editorial Material Medicine, General & Internal

Alopecia areata: baricitinib lets the hair back to grow

Susanne Krome

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT (2022)

添加到收藏夹

Article Dermatology

34301 The relationship between the degree of scalp hair loss and health-related quality of life among patients with alopecia areata

Emily Edson-Heredia et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Two Phase 3 Trials of Baricitinib for Alopecia Areata

Brett King et al.

Summary: In two clinical trials, baricitinib treatment showed superiority in promoting hair regrowth in patients with severe alopecia areata, but longer trials are needed to evaluate its efficacy and safety.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Review Dermatology

Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: A systematic review

Atrin Toussi et al.

Summary: This systematic review examines the psychosocial comorbidities, health-related quality of life, and treatment options targeting psychosocial well-being in adult and pediatric AA patients. The findings suggest that AA patients commonly have psychiatric comorbidities, especially anxiety and depression, leading to reduced health-related quality of life. Psychotherapy is often recommended as adjuvant treatment to address the substantial psychosocial impact of AA on patients.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

添加到收藏夹

Article Dermatology

Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study

Brett King et al.

Summary: The study evaluated the efficacy and safety of baricitinib in patients with alopecia areata. The results showed that baricitinib was effective in patients with >= 50% scalp hair loss and well tolerated, supporting its use in this patient population.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

添加到收藏夹

Article Dermatology